Hepatic steatosis after switching to integrase inhibitor-based regimens does not parallel short-term weight gain-Reference-Cited by-同舟云学术

Hepatic steatosis after switching to integrase inhibitor-based regimens does not parallel short-term weight gain

Published:2023-10-26 Issue:14 Volume:37 Page:2259-2262
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Gonzalez-Serna Alejandro¹²³,Macías Juan¹³⁴,Rincon Pilar¹³,Arriaza Maria Jose¹³,Corma-Gomez Anais¹³,Santos Marta¹³,Fernandez-Fuertes Marta¹³,Pineda Juan Antonio¹³⁴,Real Luis Miguel¹³⁴⁵

Affiliation:

1. Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen de Valme/CSIC/Universidad de Sevilla

2. Departamento de Fisiología, Facultad de Farmacia, Universidad de Sevilla, Sevilla

3. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid

4. Departamento de Medicina, Universidad de Sevilla

5. Departamento de Bioquímica Médica y Biología Molecular e Inmunología, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain.

Abstract

We studied hepatic steatosis in people with HIV (PWH) who switched to an integrase inhibitor (INSTI)-based regimen. One hundred and fifty-four PWH were included. After 48 weeks, median (Q1–Q3) weight gain was 1.2 (−0.6 to 3.8) kg and median (Q1–Q3) controlled attenuation parameter (CAP) change was −4 (−33 to 27) dB/m. Weight gain was weakly correlated with CAP change [R 2 95% confidence interval (CI) = 0.144 (−0.014 to 0.296); P = 0.074)]. Changes in hepatic steatosis after switching to INSTI-based regimens do not seem to parallel weight gain after 1 year.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference15 articles.

1. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada;Bourgi;J Int AIDS Soc,2020

2. Dolutegravir-based or low-dose efavirenz-based regimen for the treatment of HIV-1;Kouanfack;N Engl J Med,2019

3. Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients;Macías;HIV Med,2016

4. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients;Macías;AIDS,2014

5. Non-alcoholic fatty liver disease in HIV infection;Macías;AIDS Rev,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatic Steatosis and Weight Gain During the Coronavirus Disease 2019 Pandemic Among People With Human Immunodeficiency Virus: Impact of Therapy With Tenofovir Alafenamide;Open Forum Infectious Diseases;2023-10-31